Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Recursion Pharmaceuticals Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.31 (market cap $2.98B), while Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is the larger of the two by market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FNGU | RXRX | |
|---|---|---|
Market Cap | $2.98B | $2.14B |
Volume | 4,682,352 | 30,789,535 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $6.79 |
52-Week Low | $13.73 | $2.84 |
Typical Hold Time | 19 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.31, down 2.39% today. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETN faces significant volatility risks, having lost 87% during previous tech sector downturns according to 247 Wallst analysis from August 19, 2026.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest near-term upside potential to resistance at $37-39, the extreme volatility and concentration in mega-cap tech stocks present substantial downside risks during market corrections. Investors require high risk tolerance for this instrument.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
